Anti-CD19 chimeric antigen receptor T-cell therapy for relapsed or refractory Philadelphia chromosome-positive B cell acute lymphoblastic leukemia: a multicenter retrospective study
Key Points
The aim is to evaluate the effectiveness of anti-CD19 CAR T-cell therapy in patients with relapsed or refractory Philadelphia chromosome-positive B cell acute lymphoblastic leukemia.
Conducted a multicenter retrospective analysis
Included patients with relapsed or refractory leukemia
Assessed outcomes following anti-CD19 CAR T-cell therapy
Observed significant responses in a subset of patients
Demonstrated potential benefits in survival rates
Highlighted the therapy's role in treatment-resistant cases
Abstract
The preliminary study was presented as a poster presentation (Publication Number: 4201) at the 66th American Society of Hematology Annual Meeting, San Diego, CA, on December 7-10, 2024.
Anti-CD19 chimeric antigen receptor T-cell therapy for relapsed or refractory Philadelphia chromosome-positive B cell acute lymphoblastic leukemia: a multicenter retrospective study | Synapse
Also Consider
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation2012 · 465 citations